Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
01/10/2026 12:31
BRIEF-Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment Oct 1 (Reuters) - Nektar Therapeutics NKTR.O:
NEKTAR THERAPEUTICS - REZPEGALDESLEUKIN DEMONSTRATES DURABILITY AND DEEPENING OF RESPONSE THROUGH ONE YEAR OF TREATMENT
NEKTAR THERAPEUTICS - SALT SCORE ≤20 RESPONSE MAINTAINED IN 75% AT 4 MONTHS, 63% AT 6 MONTHS OFF TREATMENT
NEKTAR THERAPEUTICS - 19% ACHIEVE SALT SCORE ≤10 AT 6 MONTHS OFF TREATMENT, UP FROM 7% AT 52 WEEKS
NEKTAR THERAPEUTICS - PHASE 3 ZENITH AA STUDY TO INITIATE IN EARLY 2027
NEKTAR THERAPEUTICS - REZPEGALDESLEUKIN SAFETY PROFILE THROUGH 52 WEEKS FAVORABLE AND CONSISTENT WITH PREVIOUS REPORTS
Source text: ID:nPn5WJXsKa
Further company coverage: NKTR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says